1. (valid email required)

cforms contact form by delicious:days

Caliper Life Sciences completes previously announced CRi acquisition

February 3, 2011

Adds Proprietary Multiplexed In Vivo and Tissue Imaging Technology to Caliper’s Leading Portfolio of Drug Discovery, Imaging and Diagnostics Solutions

Hopkinton, Massachusetts – December 21, 2010 - Caliper Life Sciences, Inc. (Nasdaq: CALP), a leading provider of products and services for drug discovery research, announced that it has completed the acquisition of privately-held Cambridge Research & Instrumentation, Inc. (CRi) pursuant to the terms of the merger agreement previously announced on December 9, 2010. Caliper paid approximately $20 million in consideration for all of CRi’s outstanding equity securities, which consisted of approximately $7.9 million in cash, approximately $1.8 million of assumed debt, and approximately 1.6 million shares of its common stock valued at approximately $10.3 million.

“We are excited to have completed this transaction which adds CRi’s proprietary multiplexed in vivo and tissue imaging technology to Caliper’s leading portfolio of drug discovery, imaging and diagnostics solutions,” said Kevin Hrusovsky, President and CEO of Caliper Life Sciences. “CRi’s products provide an entry point for Caliper to address the expanding billion-dollar tissue imaging and digital pathology clinical research market. In addition, CRi’s technologies enhance our toolkit of proprietary technologies for creating new product solutions to advance our vision to transform “sick care” to “health care” through next generation biomarker discovery, patient stratification studies and companion diagnostics for personalized medicine. We are pleased to welcome CRi to the Caliper team.”

About Caliper Life Sciences

Caliper Life Sciences is a premier provider of cutting-edge technologies enabling researchers in the life sciences industry to create life-saving and enhancing medicines and diagnostic tests more quickly and efficiently. Caliper is aggressively innovating new technology to bridge the gap between in vitro assays and in vivo results, enabling the translation of those results into cures for human disease. Caliper’s portfolio of offerings includes state-of-the-art microfluidics, lab automation and liquid handling, optical imaging technologies, and discovery and development outsourcing solutions. For more information please visit www.caliperLS.com.

About CRi, Inc.

Cambridge Research & Instrumentation (CRi) develops and markets optical imaging systems to advance biomedical research and molecular-based drug and diagnostic development. CRi’s patented systems enable researchers and clinicians to quantify multiple disease and drug response markers in intact tissue samples, at a cellular level or in living small animals. CRi’s products integrate a unique multispectral imaging technology with proprietary image analysis algorithms to achieve unparalleled accuracy and sensitivity, rapidly and cost-effectively. CRi’s award-winning systems include Nuance™ and TRIO™ for multispectral imaging on brightfield and fluorescence microscopes; inForm™ automated image analysis software; Vectra™ for high-throughput slide imaging and analysis; and Maestro™ for in-vivo optical imaging. Learn more at www.cri-inc.com.

Caliper is a trademark of Caliper Life Sciences, Inc. CRi, Nuance, TRIO, inForm, Vectra, and Maestro are trademarks of Cambridge Research & Instrumentation, Inc.

Investor Contact:

Peter McAree

Caliper Life Sciences


Media Contact:

Benjamin Navon/Kristin Villiotte

Schwartz Communications



Latest News

Dynasil Corporation of America (NASDAQ:DYSL) is pleased to announce our new website is now available at www.dynasil.com

NWN Corporation Obtains Cisco’s Elite Partnership Status In Their OpenDNS Certification Partner Program

NWN Corporation Named to CRN’s 2016 IT Solutions Provider 500 List

ACT Government leads in waste innovation

Zenoss Names NWN Corporation as Managed IT Service Provider of The Year For Second Year In a Row

Datawatch Enables 450 CNAF Accountants to Prep Less and Analyze More

NWN Completes “Cisco Mega Audit” – Achieves Multiple “Master” Certifications

Best Practices for Pharmaceutical Waste

Latest Newsletters

July 2016 – Mass Capital Announces a New Investment in The Cadmus Group, Inc.

April 2016 – Andrew DeLorey joins Mass Capital

March 2016 – Mass Capital announces a new investment in Valet Park of America

January 2016 – Mass Capital announces a new investment in Phillips Screw Company

November 2015 – Mass Capital announces a new investment in Triumvirate Environmental

September 2015 – Mass Capital announces a new investment in MedTouch

September Newsletter 2014

Mass. Capital Announces Addition to Investment Team